1stOncology™: Cancer Intelligence Service – Page 34 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

On September 11, 2026 Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, reported that the Company will participate in the H.C. Wainwright 28th Annual Global Investment Conference, taking place in New York City September 14-16, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

On Wednesday, September 16, 2026, at 10:30 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, Charles Morris, MBChB, MRCP. Chief Medical Officer, Peggy Scherle, Ph.D., Chief Scientific Officer, and Bryant Lim, Chief Financial Officer will participate in a fireside chat.

A live webcast of the fireside chat can be accessed on the Company’s website under Events and Presentations. The recording will be archived and available on the Company’s website for 90 days.

(Press release, Prelude Therapeutics, SEP 11, 2026, https://www.globenewswire.com/news-release/2026/09/11/3360242/0/en/prelude-therapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference.html [SID1234670762])

ABL Diagnostics (ABLD) Announces the Filing of a Takeover Bid for Integragen

On September 11, 2026 ABL Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6) (the "Company"), a company specialized in molecular diagnostics solutions, healthcare software and services supporting clinical research, reported that it has filed, on Friday, September 11, 2026, a bid to acquire the business operations and assets of IntegraGen, a company specializing in genomic analysis of nucleic acids, particularly in oncology and rare genetic diseases, currently subject to judicial reorganization proceedings before the Commercial Court of Évry.

This initiative is consistent with ABL Diagnostics’ growth strategy and its ongoing evaluation of external growth opportunities complementary to its current portfolio.

The proposed acquisition, filed pursuant to Article L.642-1 of the French Commercial Code, remains subject to the decision of the Commercial Court of Évry. At this stage, there can be no assurance that ABL Diagnostics will be selected as the successful bidder.

The Company will keep the market informed of any material developments regarding this matter in accordance with applicable regulatory requirements.

Regulatory Information

This press release contains inside information within the meaning of Article 7 of Regulation (EU) No. 596/2014 on market abuse ("MAR"). Its disclosure is made in accordance with Article 17 of MAR. Forward-looking statements contained herein are inherently subject to risks and uncertainties, including those related to the outcome of judicial proceedings and the approval of third parties.

(Press release, Integragen, SEP 11, 2026, View Source [SID1234670761])

Owkin to License K Pro and Multimodal Data to Servier to Advance Oncology Research

On September 11, 2026 Owkin, the agentic AI company pioneering the first automated AI scientist to revolutionize drug discovery and development, reported an agreement with Servier, an independent international pharmaceutical group governed by a foundation, to license K Pro, Owkin’s AI Scientist, together with multimodal patient data to advance the company’s oncology research.

Under the agreement, Owkin will make multimodal patient data from its MOSAIC network accessible for analysis to Servier’s research teams, within K Pro. This agreement is the next chapter in Owkin and Servier’s collaboration, their previous work together being in patient subgroup identification, also in oncology.

K Pro is Owkin’s AI scientist. It brings multimodal patient data and specialized biological agentic AI to drive smarter and faster decision-making to each step of the pharmaceutical value chain. K Pro utilizes specialized biological tools, leveraging a decade of knowledge gained through pharmaceutical partnerships and state-of-the-art AI research. K Pro delivers molecule optimization, target discovery, biomarker identification, subgroup optimization and clinical trial design. K Pro is trained and validated on real-world patient data and through Owkin’s wet lab.

"Our AI scientist is changing the way biopharma works," said Thomas Clozel, CEO and co-founder of Owkin. "By pairing K Pro with Owkin’s multimodal patient data, Servier’s scientists can investigate the biology of hard-to-treat cancers and reach answers that manual analysis alone cannot deliver."

"At Servier, we are constantly looking for new ways to deepen our understanding of disease biology and to bring better treatments to patients with hard-to-treat cancers. Access to high-quality patient data and AI-driven analysis in one place, through K Pro, helps our teams generate and test hypotheses with greater speed and confidence. We look forward to applying these capabilities across our oncology research," said Claude Bertrand, Executive Vice President, Research & Development, Servier.

(Press release, Owkin, SEP 11, 2026, View Source [SID1234670760])

Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

On September 11, 2026 Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing therapeutics based on its proprietary INTASYL siRNA gene-silencing technology designed to eliminate cancer, reported that members of its management team will be available for one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, at the Lotte New York Palace Hotel in New York City.

Robert Bitterman, President and Chief Executive Officer, and Lisa Carson, Chief Financial Officer, will be available for meetings with investors throughout the conference. At the conference, management will discuss the Company’s clinical lead candidate PH-762, strategic priorities, and upcoming initiatives designed to support continued execution and long-term value creation.

Phio Pharmaceuticals’ Presentation
A webcast of Phio Pharmaceuticals’ presentation is available through the following link: Journey

Conference Details
Event: H.C. Wainwright 28th Annual Global Investment Conference
Dates: September 14-16, 2026
Location: Lotte New York Palace Hotel, New York, NY

(Press release, Phio Pharmaceuticals, SEP 11, 2026, https://phiopharma.com/phio-pharmaceuticals-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference/ [SID1234670758])

Sona Nanotech to Present at the OTC Markets’ Life Sciences Virtual Investor Forum On September 17th

On September 11, 2026 Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF), an oncology company developing a therapy to increase the limited efficacy of immunotherapy drugs, reported that David Regan, CEO, will present live at the OTC Markets’ Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on September 17th, 2026.

DATE: September 17th

TIME: 11:00 am EDT

Schedule 1×1 meetings here.

The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportunity to submit questions to management in real time. A replay of the webcast will be available following the conclusion of the conference.

Mr. Regan will be presenting on Sona’s promising clinical stage, solid cancer treatment, Targeted Hyperthermia Therapy, and how it may enable greater efficacy of some of today’s blockbuster drugs and thereby return significant value to investors.

It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.

Learn more about the event at www.virtualinvestorconferences.com.

Recent Company Highlights

Sona’s Targeted Hyperthermia Therapy ("THT") caused an immune system response in 8/10 biopsied tumors, with 6/10 no longer showing signs of cancer, in late stage melanoma patients who had failed on standard immunotherapy drugs.
Gearing up for a study to assess the further benefits and safety of THT when combined with immunotherapy drugs in patients that previously failed on them.
THT, which used inert gold nanorods to prime tumors, has shown excellent safety.
Clinical strategy is supported by significant pre-clinical research published in peer-reviewed scientific journals and an experienced board and management team.

(Press release, Sona Nanotech, SEP 11, 2026, View Source [SID1234670756])